Pandemic-Induced Innovation and Adaptation
with Insights from McKinsey & Company
REGISTER TODAY!
|
Virtual Program: Wednesday, September 29, 2021 | 8:45 a.m.-2:15 p.m. |
Biopharma manufacturing has been evolving rapidly and even more since COVID-19. Join us for BioNJ’s Manufacturing Briefing on September 29 where you’ll hear from and engage with industry thought leaders on important topics, including trends, best practices and lessons learned in vaccines and therapeutics manufacturing including the emergence of new technologies…in light of unprecedented supply chain demand and resiliency… all compounded by the impact of working remotely.
Take a look at the agenda…
Additional speakers being added!
|
8:45 a.m. – 9:00 a.m.
|
Welcome & Opening Remarks
 |
Debbie Hart, President & CEO, BioNJ
|
|
9:00 a.m. – 9:30 a.m.
|
Setting the Stage
Kickstart the day with an insightful perspective on how the industry responded and adapted to the pandemic and how these changes will shape the future of the industry.
 |
Andrea Gennari, MBA, Partner, McKinsey & Company
|
|
9:30 a.m. – 10:30 a.m.
|
Panel: Vaccines & Therapeutics – Emergence of New Technologies & Approaches
Big trends in COVID-19 vaccines and therapeutics during the pandemic featuring best practices, lessons learned and the emergence of new technologies…at lightning speed to market.
Panelists:
|
 |
Annalisa Caterina Barile, Vice President and General Manager, Pharma Services Group, ThermoFisher Scientific
|
 |
Ryan Saadi, M.D., MPH, Chairman & Chief Executive Officer, Tevogen Bio
|
 |
Pamela Siwik, MBA, Vice President, Pfizer Global Supply, New Modalities New Product Lead, Pfizer
|
Moderator:
|
 |
Katie Kelleher, MBA, Associate Partner, McKinsey & Company
|
|
10:30 a.m. – 11:00 a.m.
|
Fireside Chat: The Moderna Story with Two Moderna Leaders
This conversation will highlight the riveting Moderna journey in getting the COVID-19 vaccine approved, manufactured and into the marketplace in record time, including getting non-existent manufacturing facilities and supply chain systems up and running as well as materials, workforce and site challenges along the way.
 |
Juan Andres, Chief Technical Operations and Quality Officer, Moderna
|
 |
Francois Nader, M.D., MBA, Independent Board Director, Moderna
|
|
11:00 a.m. – 11:15 a.m.
|
Break
|
11:15 a.m. – 12:15 p.m.
|
Panel: Impact of COVID-19 on Broader Pharma Manufacturing & Supply Chain
The effects of the COVID-19 pandemic on the broader biopharma network are and will continue to be real and dramatic, including supply chain resiliency, increased demand faced by suppliers and impact of working remotely. This session will feature experts who are grappling with, recovering from and building on the fallout.
Panelist:
|
 |
Melissa Buchanan, MBA, Director, Supply Chain, Catalent Biologics
|
 |
Jackie Elbonne, Ph.D., Chief Quality Officer & Senior Vice President of Global Quality, Bristol-Myers Squibb
|
 |
Peter Levison, Ph.D., MBA, Executive Director, Business Development, Pall Corporation
|
Moderator:
|
 |
Derron Stark, MBA, Managing Director, Strategy & Transactions, EY-Parthenon
|
|
12:15 p.m. – 12:45 p.m.
|
Case Study: Lessons Learned that are Here to Stay Beyond the Pandemic
The pandemic posed a unique set of challenges and required nimble responses to maintain manufacturing operations, ensure workforce safety and maximize supply chain resiliency. Hear a case study on how Thermo Fisher Scientific answered the call along with lasting takeaways for a post-pandemic world.
 |
Konrad Bauer, Senior Vice President, Global Business Services, Thermo Fisher Scientific
|
|
12:45 p.m. – 1:00 p.m.
|
Break
|
1:00 p.m. – 1:45 p.m.
|
Keynote by Dr. Carlo De Notaristefani
Having had a hand in and a bird’s-eye view of the U.S. Government’s response to the pandemic and the rollout of the various vaccines, Dr. DeNotaristefani will provide a compelling and insightful account of his perspective.
 |
Carlo De Notaristefani, Dr. Ing., Lead Advisor for Manufacturing & Supply Chain, Operation Warp Speed/Federal COVID-19 Response, CDN Advising
|
|
1:45 p.m. – 2:15 p.m.
|
Networking: Pain Points in the Industry
Engage with other industry professionals in breakout rooms where we’ll discuss:
 |
Addressing Talent Challenges in Manufacturing
Topic Leader: Norm Stoffregen, Head of Gene Therapy Biologics, PTC Therapeutics
|
 |
Application of Industry 4.0 to Manufacturing of Cell & Gene Therapies
Topic Leader: Amy Lamperti, Vice President, Commercialization, BioCentriq
|
 |
Challenges in GMP Facility Buildout
Topic Leaders: David Kristjanson, PMP, Vice President, Life Sciences Advisory, CBRE Life Sciences Group
|
 |
Tom Sullivan, Senior Vice President, CBRE Life Sciences Group
|
|
Sponsored by: